Cargando…

Characterisation of the pro-inflammatory cytokine signature in severe COVID-19

Clinical outcomes from infection with SARS-CoV-2, the cause of the COVID-19 pandemic, are remarkably variable ranging from asymptomatic infection to severe pneumonia and death. One of the key drivers of this variability is differing trajectories in the immune response to SARS-CoV-2 infection. Many s...

Descripción completa

Detalles Bibliográficos
Autores principales: Hawerkamp, Heike C., Dyer, Adam H., Patil, Neha D., McElheron, Matt, O’Dowd, Niamh, O’Doherty, Laura, Mhaonaigh, Aisling Ui, George, Angel M., O’Halloran, Aisling M., Reddy, Conor, Kenny, Rose Anne, Little, Mark A., Martin-Loeches, Ignacio, Bergin, Colm, Kennelly, Sean P., Donnelly, Seamas C., Bourke, Nollaig M., Long, Aideen, Sui, Jacklyn, Doherty, Derek G., Conlon, Niall, Cheallaigh, Cliona Ni, Fallon, Padraic G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101230/
https://www.ncbi.nlm.nih.gov/pubmed/37063871
http://dx.doi.org/10.3389/fimmu.2023.1170012
_version_ 1785025464886099968
author Hawerkamp, Heike C.
Dyer, Adam H.
Patil, Neha D.
McElheron, Matt
O’Dowd, Niamh
O’Doherty, Laura
Mhaonaigh, Aisling Ui
George, Angel M.
O’Halloran, Aisling M.
Reddy, Conor
Kenny, Rose Anne
Little, Mark A.
Martin-Loeches, Ignacio
Bergin, Colm
Kennelly, Sean P.
Donnelly, Seamas C.
Bourke, Nollaig M.
Long, Aideen
Sui, Jacklyn
Doherty, Derek G.
Conlon, Niall
Cheallaigh, Cliona Ni
Fallon, Padraic G.
author_facet Hawerkamp, Heike C.
Dyer, Adam H.
Patil, Neha D.
McElheron, Matt
O’Dowd, Niamh
O’Doherty, Laura
Mhaonaigh, Aisling Ui
George, Angel M.
O’Halloran, Aisling M.
Reddy, Conor
Kenny, Rose Anne
Little, Mark A.
Martin-Loeches, Ignacio
Bergin, Colm
Kennelly, Sean P.
Donnelly, Seamas C.
Bourke, Nollaig M.
Long, Aideen
Sui, Jacklyn
Doherty, Derek G.
Conlon, Niall
Cheallaigh, Cliona Ni
Fallon, Padraic G.
author_sort Hawerkamp, Heike C.
collection PubMed
description Clinical outcomes from infection with SARS-CoV-2, the cause of the COVID-19 pandemic, are remarkably variable ranging from asymptomatic infection to severe pneumonia and death. One of the key drivers of this variability is differing trajectories in the immune response to SARS-CoV-2 infection. Many studies have noted markedly elevated cytokine levels in severe COVID-19, although results vary by cohort, cytokine studied and sensitivity of assay used. We assessed the immune response in acute COVID-19 by measuring 20 inflammatory markers in 118 unvaccinated patients with acute COVID-19 (median age: 70, IQR: 58-79 years; 48.3% female) recruited during the first year of the pandemic and 44 SARS-CoV-2 naïve healthy controls. Acute COVID-19 was associated with marked elevations in nearly all pro-inflammatory markers, whilst eleven markers (namely IL-1β, IL-2, IL-6, IL-10, IL-18, IL-23, IL-33, TNF-α, IP-10, G-CSF and YKL-40) were associated with disease severity. We observed significant correlations between nearly all markers elevated in those infected with SARS-CoV-2 consistent with widespread immune dysregulation. Principal component analysis highlighted a pro-inflammatory cytokine signature (with strongest contributions from IL-1β, IL-2, IL-6, IL-10, IL-33, G-CSF, TNF-α and IP-10) which was independently associated with severe COVID-19 (aOR: 1.40, 1.11-1.76, p=0.005), invasive mechanical ventilation (aOR: 1.61, 1.19-2.20, p=0.001) and mortality (aOR 1.57, 1.06-2.32, p = 0.02). Our findings demonstrate elevated cytokines and widespread immune dysregulation in severe COVID-19, adding further evidence for the role of a pro-inflammatory cytokine signature in severe and critical COVID-19.
format Online
Article
Text
id pubmed-10101230
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101012302023-04-14 Characterisation of the pro-inflammatory cytokine signature in severe COVID-19 Hawerkamp, Heike C. Dyer, Adam H. Patil, Neha D. McElheron, Matt O’Dowd, Niamh O’Doherty, Laura Mhaonaigh, Aisling Ui George, Angel M. O’Halloran, Aisling M. Reddy, Conor Kenny, Rose Anne Little, Mark A. Martin-Loeches, Ignacio Bergin, Colm Kennelly, Sean P. Donnelly, Seamas C. Bourke, Nollaig M. Long, Aideen Sui, Jacklyn Doherty, Derek G. Conlon, Niall Cheallaigh, Cliona Ni Fallon, Padraic G. Front Immunol Immunology Clinical outcomes from infection with SARS-CoV-2, the cause of the COVID-19 pandemic, are remarkably variable ranging from asymptomatic infection to severe pneumonia and death. One of the key drivers of this variability is differing trajectories in the immune response to SARS-CoV-2 infection. Many studies have noted markedly elevated cytokine levels in severe COVID-19, although results vary by cohort, cytokine studied and sensitivity of assay used. We assessed the immune response in acute COVID-19 by measuring 20 inflammatory markers in 118 unvaccinated patients with acute COVID-19 (median age: 70, IQR: 58-79 years; 48.3% female) recruited during the first year of the pandemic and 44 SARS-CoV-2 naïve healthy controls. Acute COVID-19 was associated with marked elevations in nearly all pro-inflammatory markers, whilst eleven markers (namely IL-1β, IL-2, IL-6, IL-10, IL-18, IL-23, IL-33, TNF-α, IP-10, G-CSF and YKL-40) were associated with disease severity. We observed significant correlations between nearly all markers elevated in those infected with SARS-CoV-2 consistent with widespread immune dysregulation. Principal component analysis highlighted a pro-inflammatory cytokine signature (with strongest contributions from IL-1β, IL-2, IL-6, IL-10, IL-33, G-CSF, TNF-α and IP-10) which was independently associated with severe COVID-19 (aOR: 1.40, 1.11-1.76, p=0.005), invasive mechanical ventilation (aOR: 1.61, 1.19-2.20, p=0.001) and mortality (aOR 1.57, 1.06-2.32, p = 0.02). Our findings demonstrate elevated cytokines and widespread immune dysregulation in severe COVID-19, adding further evidence for the role of a pro-inflammatory cytokine signature in severe and critical COVID-19. Frontiers Media S.A. 2023-03-30 /pmc/articles/PMC10101230/ /pubmed/37063871 http://dx.doi.org/10.3389/fimmu.2023.1170012 Text en Copyright © 2023 Hawerkamp, Dyer, Patil, McElheron, O’Dowd, O’Doherty, Mhaonaigh, George, O’Halloran, Reddy, Kenny, Little, Martin-Loeches, Bergin, Kennelly, Donnelly, Bourke, Long, Sui, Doherty, Conlon, Cheallaigh and Fallon https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Hawerkamp, Heike C.
Dyer, Adam H.
Patil, Neha D.
McElheron, Matt
O’Dowd, Niamh
O’Doherty, Laura
Mhaonaigh, Aisling Ui
George, Angel M.
O’Halloran, Aisling M.
Reddy, Conor
Kenny, Rose Anne
Little, Mark A.
Martin-Loeches, Ignacio
Bergin, Colm
Kennelly, Sean P.
Donnelly, Seamas C.
Bourke, Nollaig M.
Long, Aideen
Sui, Jacklyn
Doherty, Derek G.
Conlon, Niall
Cheallaigh, Cliona Ni
Fallon, Padraic G.
Characterisation of the pro-inflammatory cytokine signature in severe COVID-19
title Characterisation of the pro-inflammatory cytokine signature in severe COVID-19
title_full Characterisation of the pro-inflammatory cytokine signature in severe COVID-19
title_fullStr Characterisation of the pro-inflammatory cytokine signature in severe COVID-19
title_full_unstemmed Characterisation of the pro-inflammatory cytokine signature in severe COVID-19
title_short Characterisation of the pro-inflammatory cytokine signature in severe COVID-19
title_sort characterisation of the pro-inflammatory cytokine signature in severe covid-19
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101230/
https://www.ncbi.nlm.nih.gov/pubmed/37063871
http://dx.doi.org/10.3389/fimmu.2023.1170012
work_keys_str_mv AT hawerkampheikec characterisationoftheproinflammatorycytokinesignatureinseverecovid19
AT dyeradamh characterisationoftheproinflammatorycytokinesignatureinseverecovid19
AT patilnehad characterisationoftheproinflammatorycytokinesignatureinseverecovid19
AT mcelheronmatt characterisationoftheproinflammatorycytokinesignatureinseverecovid19
AT odowdniamh characterisationoftheproinflammatorycytokinesignatureinseverecovid19
AT odohertylaura characterisationoftheproinflammatorycytokinesignatureinseverecovid19
AT mhaonaighaislingui characterisationoftheproinflammatorycytokinesignatureinseverecovid19
AT georgeangelm characterisationoftheproinflammatorycytokinesignatureinseverecovid19
AT ohalloranaislingm characterisationoftheproinflammatorycytokinesignatureinseverecovid19
AT reddyconor characterisationoftheproinflammatorycytokinesignatureinseverecovid19
AT kennyroseanne characterisationoftheproinflammatorycytokinesignatureinseverecovid19
AT littlemarka characterisationoftheproinflammatorycytokinesignatureinseverecovid19
AT martinloechesignacio characterisationoftheproinflammatorycytokinesignatureinseverecovid19
AT bergincolm characterisationoftheproinflammatorycytokinesignatureinseverecovid19
AT kennellyseanp characterisationoftheproinflammatorycytokinesignatureinseverecovid19
AT donnellyseamasc characterisationoftheproinflammatorycytokinesignatureinseverecovid19
AT bourkenollaigm characterisationoftheproinflammatorycytokinesignatureinseverecovid19
AT longaideen characterisationoftheproinflammatorycytokinesignatureinseverecovid19
AT suijacklyn characterisationoftheproinflammatorycytokinesignatureinseverecovid19
AT dohertyderekg characterisationoftheproinflammatorycytokinesignatureinseverecovid19
AT conlonniall characterisationoftheproinflammatorycytokinesignatureinseverecovid19
AT cheallaighclionani characterisationoftheproinflammatorycytokinesignatureinseverecovid19
AT fallonpadraicg characterisationoftheproinflammatorycytokinesignatureinseverecovid19